Diagnosis and Treatment of Venous Thromboembolism

Department of Medicine, McMaster University, Hamilton Health Sciences, Henderson Site, 711 Concession Street, Hamilton, Ontario, L8V 1C3, Canada.
Annual Review of Medicine (Impact Factor: 12.93). 02/2002; 53(1):15-33. DOI: 10.1146/
Source: PubMed


The diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE) has been improved and simplified over the past decade thanks to advances in noninvasive and readily accessible technology. With high degrees of sensitivity and specificity, venous ultrasonography is favored as the initial investigation for DVT. To diagnose PE, most clinicians rely on diagnostic algorithms that combine clinical assessment, noninvasive lung studies, and, if necessary, venous ultrasonography of the legs and D-dimer testing. Substantial progress has also occurred in the treatment of acute venous thromboembolism with the introduction of low-molecular-weight heparins. This class of antithrombotic agents has changed initial therapy from an inpatient, intravenous regimen that required laborious monitoring to an outpatient practice using weight-adjusted doses of once-daily subcutaneous injections. In addition, several new anticoagulants with theoretical advantages over existing agents have entered phase III studies. Aspects of thrombosis treatment that remain controversial include vena caval interruption and the indications for thrombolysis and surgical thromboembolectomy.

Download full-text


Available from: Jack Hirsh
  • Source
    • "The main challenge in the diagnostic workup of patients with clinically suspected pulmonary embolism is to accurately and rapidly distinguish the approximately 25% of patients who have the disease and require anticoagulant treatment from the 75% who do not [2] [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary embolism is one of the greatest diagnostic challenges in emergency medicine and clinical probability assessment is a fundamental step in its diagnosis.AimTo evaluate the role of estimating clinical probability of pulmonary embolism and to compare between different pre-test probability scoring systems as regards their sensitivity and specificity.Patients and methodsWe used seven scoring systems (original Geneva score, revised Geneva score, simplified Geneva score, Wells score, simplified Wells score, simplified Charlotte rule, Pisa model) to assess the clinical probability of PE in 41 patients with suspected pulmonary embolism for whom the final diagnosis was based on multislice CT pulmonary angiography (CTPA).ResultsTwenty-four patients (58.5%) had pulmonary embolism. The scores with the strongest correlation with the result of CTPA were the Pisa model (P ⩽ 0.001) followed by the original Geneva score and the Wells score (P ⩽ 0.01). Simplified Wells score had the highest sensitivity (0.92), Pisa model had the highest specificity (0.82) and the highest overall accuracy (0.76).Conclusion For most patients, clinical probability assessment is an easy and effective way to decide which patient should undergo further investigations. Among the studied seven scores, the Pisa model has the best correlation with the CTPA results and it has a good sensitivity, specificity, positive and negative predictive values and the highest overall accuracy.
    Full-text · Article · Oct 2012
  • Source
    • "Less than two decades of its discovery, the pathophysiology , clinical consequences, and therapeutic management of the thrombophilic state associated to this condition remains object of controversies [6]. The excessive clotting that occurs in this FV disorder is mostly restricted to the venous territory and it's known to be the most frequent contributors to cause deep vein thrombosis (DVT) [7] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Factor V Leiden, is a variant of human factor V (FV), also known as proaccelerin, which leads to a hypercoagulable state. Along these years, factor V Leiden (FVL) has been studied from the pathophysiologic point of view, and research has been focused on finding clinical approaches for the management of the FVL associated to a trombophilic state. Less attention has been paid about the possible role of FVL in inflammatory conditions known to be present in different disorders such as uremia, cirrhosis, liver transplantation, depression as well as sepsis, infection or, inflammatory bowel disease (IBD). Whether platelet FVL will increase the activation of coagulation and/or in which proportion is able to determine the final outcome in the previously mentioned inflammatory conditions is a subject that remains uncertain. This paper will review the association of FVL with inflammation. Specifically, it will analyze the important role of the endothelium and the contribution of other inflammatory components involved at both the immune and vascular levels. This paper will also try to emphasize the importance of being a FVL carrier in associations to diseases where a chronic inflammation occurs, and how this condition may be determinant in the progression and outcome of a specific clinic situation.
    Full-text · Article · May 2012
  • Source
    • "These results supported the safety of nattokinase intake, at least for the 2-month ingestion period. On the other hand, most of the treatment options for thrombosis, such as use of anticoagulants, antiplatelet or clot-dissolving agents, might cause abnormal bleeding and, therefore, result in serious consequences [33] [34] [35]. In this study, the plasma levels of fibrinogen and factors VII and VIII showed a continuous decreasing pattern during the administration period. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nattokinase, a serine proteinase from Bacillus subtilis, is considered to be one of the most active functional ingredients found in natto. In this study, we hypothesized that nattokinase could reduce certain factors of blood clotting and lipids that are associated with an increase risk for cardiovascular disease (CVD). Thus, an open-label, self-controlled clinical trial was conducted on subjects of the following groups: healthy volunteers (Healthy Group), patients with cardiovascular risk factors (Cardiovascular Group), and patients undergoing dialysis (Dialysis Group). All subjects ingested 2 capsules of nattokinase (2000 fibrinolysis units per capsule) daily orally for 2 months. The laboratory measurements were performed on the screening visit and, subsequently, regularly after the initiation of the study. The intent-to-treat analysis was performed on all 45 enrolled subjects. By use of mixed model analysis, a significant time effect, but not group effect, was observed in the change from baseline of fibrinogen (P = .003), factor VII (P < .001), and factor VIII (P < .001), suggesting that the plasma levels of the 3 coagulation factors continuously declined during intake; also, the extents of decrease were similar between groups. After 2 months of administration, fibrinogen, factor VII, and factor VIII decreased 9%, 14%, and 17%, respectively, for the Healthy Group; 7%, 13%, and 19%, respectively, for the Cardiovascular Group; and 10%, 7%, and 19%, respectively, for the Dialysis Group, whereas blood lipids were unaffected by nattokinase. No significant changes of uric acid or notable adverse events were observed in any of the subjects. In summary, this study showed that oral administration of nattokinase could be considered as a CVD nutraceutical by decreasing plasma levels of fibrinogen, factor VII, and factor VIII.
    Full-text · Article · Apr 2009 · Nutrition research
Show more